Sternal Closure Systems Market Size Worth USD 2.96 Billion By 2025

The global sternal closure systems market size is expected to reach USD 2.96 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 5.4% during the forecast period. The market is driven by growing number of surgeries undertaken to treat complex cardiovascular problems. For instance, according to data published by American Heart Association (AHA), around 520,000 Coronary Artery Bypass Graft (CABG) surgeries were performed in the U.S. in 2014. The report further states that more than 800,000 CABG surgeries are performed worldwide every year.

Furthermore, the National Health Interview Survey conducted by CDC in 2016 concluded that 28.1 million people in the U.S. were diagnosed with heart related disorders, including valvular heart disease and cardiac arrest. Moreover, increasing research and development activities are paving way for advanced systems such as talon systems and double sternal wires. This, coupled with favorable reimbursement criteria, is bolstering market growth.

Mergers and acquisitions, new product development, and geographical expansion are key strategies adopted by players to stay ahead in the market. For instance, KLS Martin, started its sales operations in the U.K., the Netherlands, Italy, France, Australia, Russia, Dubai, Japan, Malaysia, and Brazil in last couple of years in order to increase its geographical presence. The company is also focusing on Asia Pacific due to presence of large patient pool in the region. In line with the strategy, in June 2016, the company started a manufacturing unit in Chennai, India.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/sternal-closure-systems-market

Further key findings from the report suggest:

• Rising adoption of cardiothoracic surgeries, including Coronary Artery Bypass Graft (CABG), Aortic valve surgery, and Arrhythmia surgery, is projected to augment the market
• Growing population of geriatrics across the globe is expected to stoke the growth of the market
• The closure devices segment held the leading share in the global arena in 2017, owing to introduction of technologically advanced clips and wires globally and favorable reimbursement regulations offered in developed regions such as North America and Europe
• The PEEK segment is anticipated to post significant growth over the coming years due to several benefits offered by the material, including biocompatibility, chemical resistance, end-product purity, high temperature resistance, and thermoformable nature
• North America dominated the market in 2017. The growth of the region can be attributed to presence of a large number of players and high competitive rivalry in the market. Moreover, rising adoption of technologically advanced systems coupled with presence of skilled professionals are likely to provide a fillip to the regional market
• Asia Pacific is poised to register the highest CAGR during forecast period. Increasing per capita income, improving healthcare infrastructure, and rising patient pool are estimated to drive the market
• The market is currently consolidated, with few companies capturing major shares. However, increasing demand for innovative technologies and recent market dynamics are making way for new entrants.

Gaucher Disease Drugs Market 2018 Research, Growth Opportunities, Key Players, Outlook and Forecasts Report 2025

The global gaucher disease (GD) drugs market size is expected to reach USD 1.71 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.1% during the forecast period. Growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.

Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of the organs.

In spite of being the most prevalent lysosomal storage disorder, Gaucher disease is a rare condition with an average prevalence of 1 in 100,000 individuals. However, certain ethnic races such as Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500 individuals.

Currently, type 1 is the most common form of Gaucher disease. This condition is nonneuronopathic in nature, as it does not affect the central nervous system (CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is estimated to retain its position through 2025. Type 2 and type 3 are not as common as type 1.

On the basis of treatment, enzyme replacement therapy (ERT) was the leading revenue contributor in the market in 2017. The growth of the segment can be attributed to strong sales of Cerezyme and Vpriv. However, there has been an increase in inclination towards substrate replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot penetrate blood brain barrier. Additionally, there is no effective treatment for type 2.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/gaucher-disease-drugs-market

Further key findings from the report suggest:

• Type 2 is the rarest of the three forms of GD, with average mortality rate of less than two years
• Enzyme replacement therapy dominated the treatment landscape, headed by Sanofi Genzyme’s Cerezyme. However, GD treatment is witnessing a shift towards substrate replacement therapy, which is anticipated to register a CAGR of over 7.5% during the forecast period
• The U.S. spearheaded the major markets, in terms of sales as well as disease burden. The country will continue to dominate the market through 2025, on account of widening patient base and easy accessibility to treatments
• Some of prominent companies operating in the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson
• Sanofi Genzyme led the competitive space and is projected to continue holding prominent position in the market over the coming years, due to significant commercial performances of Cerezyme and Cerdelga

Blockbuster Oncology Brands Market Size Worth USD 62.80 Billion By 2027

The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, according to a new report by Grand View Research, Inc., progressing at a CAGR of 7.3% during the forecast period. Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market.

Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo’s sales, while Revlimid’s patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immunotherapeutic is expected to trail behind the latter by 2027.

Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/blockbuster-oncology-brands-market

Further key findings from the report suggest:

• North America dominated the global arena in 2017, with approximately 65.0% share. The region is likely to maintain its position through 2027
• In terms of revenue, the lung cancer segment is estimated to expand at a CAGR of over 9.0% during the forecast period
• The multiple myeloma segment held more than 30.0% of the market revenue in 2017 and is anticipated to lose its position to lung cancer by 2027
• Europe is projected to experience modest growth during the forecast period due to delays in cost-effectiveness analysis, carried out by health technology assessment bodies, slowing approval process and lowering reimbursement
• Some of the key companies present in the market are Tesaro, Inc.; Merck &Co.; Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.

Osseointegration Implants Market Size Worth USD 9.3 Billion By 2026

The global osseointegration implants market size is expected to reach USD 9.3 billion by 2026, according to a new report by Grand View Research, Inc., registering a CAGR of 7.7% during the forecast period. Growing number of joint replacement surgeries among geriatric population, rising adoption of minimally invasive surgeries, and advancement in healthcare facilities are anticipated to drive the osseointegration implants market.

Key players have been using different strategies such as new product launch, acquisitions, partnerships, joint ventures, and agreements to increase their foothold in this market. For instance, in April 2018, Integrum SE introduced a revolutionary OPRA implant system. According to the company, the product will be initially available only in London and would be distributed through London International Patient Services (LIPS), a U.K.-based healthcare treatment organization for international patients seeking treatment.

The osseointegration implants market in developed economies, such as U.S., Germany, France, and Australia, is comparatively mature owing to presence of key market players in these countries and high demand for such products.

On the other hand, emerging countries in Asia and Latin America currently have a moderate adoption rate of these products, presenting lucrative growth opportunities in future. Economic growth and rising disposable income in these countries are anticipated to propel market growth. Manufacturing companies have been investing in these rapidly developing markets, provided pricing and distribution activities are undertaken efficiently.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/osseointegration-implants-market

Further key findings from the report suggest:

• By product, dental implants are projected to exhibit a remarkable CAGR of nearly 9.0% over the forecast period. This growth can be attributed to large number of patients along with increasing number of dental surgeries, especially in U.S. and Europe
• Asian countries are estimated to witness the highest growth in this market due to increase in penetration of market players, rising disposable income, expanding geriatric population, and surge in road traffic accidents
• Some of the key companies in the market are Medtronic, Stryker Corporation, Zimmer Biomet Holdings, Smith and Nephew Plc., Straumann AG Group, Integrum SE, and ConMed Corporation.

Vaginitis Therapeutics Market Size Worth USD 4.21 Billion By 2025

The global vaginitis therapeutics market size is expected to reach USD 4.21 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to expand at a CAGR of 8.4% during the forecast period. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.

Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/vaginitis-therapeutics-market

Further key findings from the study suggest:

• Anti-bacterial segment led the market in 2017 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease
• Hormone is expected to witness lucrative growth with a CAGR of 9.1% over the forecast period due to the presence of pipeline products and rising adoption of products
• Prescription type held the largest market share in 2017, in terms of revenue. The segment was valued at USD 1.14 billion owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis
• Over the counter is expected to be the fastest-growing type in the coming years with a CAGR of 8.7% due to increasing number of FDA approvals for the treatment of mild vaginitis
• North America is estimated to be the largest regional market. It was the dominant region in 2017, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis
• Asia Pacific is expected to be the fastest-growing region registering a lucrative CAGR over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.
• Key players in the vaginitis therapeutics market are Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; and Mission Pharmacal Company
• Most of these companies focus on strategic initiatives, such as collaborations, M&A, and product portfolio expansion. For instance, in October 2017, Lupin Pharmaceuticals acquired Symbiomix Therapeutics to expand its product portfolio.

Pharmaceutical Cartridges Market Report 2018: Global Methodology, Data Source, Marketing Channel Upcoming Trend and Forecast to 2022

The global pharmaceutical cartridges market size is expected to reach USD 1.83 billion by 2026, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 7.8% during the forecast period. Rising awareness regarding the benefits of using pharmaceutical cartridges in the packaging industry is propelling the market demand. These benefits include on-time, accurate, and safe drug delivery, break-resistance packaging, and low residual volumes of drugs. Increasing prevalence of chronic diseases, such as arthritis, diabetes, and oral conditions, and high demand for long-term storage of drugs are also anticipated to contribute toward market growth.

For instance, as per the National Diabetes Statistics Report published in 2017, American Indians were reported with the highest prevalence of diabetes for both females (15.3%) and males (14.9%). Insulin therapy plays an important role in the treatment of diabetes. Thus, growing cases of diabetes may augment the demand for insulin therapy. Previously, traditional packaging, such as blister packs and bottles, were used for insulin delivery. However, owing to several advantages, pharmaceutical cartridges are being preferred, which, in turn, is supporting market development.

In addition, various initiatives taken by prominent companies in the industry are also expected to augment the pharmaceutical cartridges market demand. For example, the chairman and CEO of Merck, stated in an article that the company is planning to convert its injectable products to the new glass packaging solution, once it receives the approval. Furthermore, in 2015, Schott AG started a center of excellence at its U.S. production facility for developing chemically-strengthened glass cartridges.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/pharmaceutical-cartridges-market

Further key findings from the study suggest:

• In terms of revenue, the glass cartridges segment is projected to expand at the fastest CAGR over the forecast period
• Increasing prevalence of chronic diseases across the globe and advantages offered by glass cartridges over the conventional ones are projected to drive the segment growth
• North America led the market in the past accounting for the largest share due to increased cases of diabetes and other chronic diseases among all age groups
• Some of the key companies in the pharmaceutical cartridges market are Gerresheimer AG; SCHOTT AG; West Pharmaceutical Services, Inc.; Merck KGaA; Stevanto Group; Transcoject GmbH; and Baxter International, Inc.

Electron Microscope Market 2018: Development History, Current Analysis and Estimated Forecast to 2025

The global electron microscope market size is expected to reach USD 5.7 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 7.4% over the forecast period. Rising investment in research and increasing use of electron microscopes in industries such as semiconductors, life sciences, and materials research Industries is anticipated to boost the market growth. Developing countries offer new investment avenues to the global market giants. The developing infrastructure and increasing research investments are driving the demand for advanced medical devices in these countries.

Microscopes are used extensively in the field of semiconductors. In the field of life sciences, they can be used in clinical trials, toxicology, pathology, diagnosis of diseases, and various other sub disciplines. Microscopy can also be used for characterization of materials, to study their internal structures, and various other applications. They are used in forensics, food industry, healthcare, and chemical among other industries.

Few of the key players in the electron microscopes market are Nikon Metrology Inc.; Thermo Fisher Scientific.; ZEISS, International; JEOL Ltd.; Angstrom Advanced Inc.; Hirox Europe Ltd.; and Hitachi High-Technologies Europe GmbH. Regional and service portfolio expansions and mergers and acquisitions are the key strategic undertakings adopted by these players. For instance, in June 2018, Thermo Fischer Scientific acquired electron microscope software console from Roper technologies.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/electron-microscopes-market

Further key findings from the study suggest:

• The global electron microscopes market was valued at USD 3.2 billion in 2017 and is expected to grow lucratively over the forecast period
• Scanning electron microscope segment is anticipated to expand at the fastest CAGR over the forecast period
• Life sciences segment captured the largest market share in 2017
• Nanotechnology is expected to witness the fastest CAGR during the forecast period owing to increasing investments
• Asia Pacific is expected to exhibit high growth over the forecast period owing to rising investments from global market players.

Flat panel detector (FPD) based x-ray for cone beam computed tomography (CBCT) market size reach USD 3.96 billion by 2025

The global flat panel detector (FPD) based x-ray for cone beam computed tomography (CBCT) market size is likely to reach USD 3.96 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.07% during the forecast period. Rising adoption of 3D imaging in medical diagnostics and application of FPD in a substantial number of CBCT systems is expected to spur the growth of the market during the forecast period.

Most of the commercially available CBCT devices operate on principle of indirect FPDs, where X-ray photons are converted to light photons using a layer of scintillator material (Caesium Iodide (CsI:Tl) or Gadolinium Oxysulfide (Gd2O2S:Tb)). These light photons are further converted into electrical signals. Higher dose efficiency and image quality are achieved using modern CsI scintillators as their columnar structure reduces the light spreading between the scintillators.

The FPD-based X-ray for CBCT market is consolidated, marked by presence of a few well-established players that account for the largest cumulative revenue share. These players have strengthened their presence by improving distribution network. However, with increasing market opportunities, the number of new entrants is estimated to rise gradually. Established players are adopting strategies such as development of a strong product line with innovative designs and expansion of service facilities on a global scale.

For instance, in April 2018, Xoran Technologies launched MiniCAT 2020, a compact, low-dose, and CBCT scanner. This product was introduced for diagnosis of sinus disease. Xoran entered the CBCT market in 2001. Furthermore, in November 2016, AFP Imaging Corporation received a license from the Canadian government for marketing of Newtom VG 3D CBCT scanner. In May 2015, PLANMED OY received FDA approval for its new CBCT system-based on FPD technology, Planmed Verity MaxScan, which is designed for maxillofacial imaging.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/fpd-based-x-ray-cbct-market

Further key findings from the report suggest:

• Orthopedics dominated the FPD-based X-ray CBCT market in 2017, owing to higher adoption of the technology for orthopedic imaging. Growing number of medical X-ray imaging for extremity application is further contributing to the growth of the segment
• With high complexity in imaging due to small and complicated bone structures in ENT, this application segment is projected to post the highest CAGR in terms of revenue during the forecast period
• FPD-based CBCT with standing patient positioning accounted for largest share in the market in 2017, due to benefits associated with their usage, including low cost, less space occupied, and higher preference for orthopedic imaging
• Hospitals represented the leading revenue share in 2017 as a consequence of higher demand from these end users for detection of anomalies and deformities prior and post surgeries
• In 2017, North America dominated the market owing to volumetric expansion of product usage coupled with presence of well-established market participants
• However, Middle East & Africa is anticipated to exhibit the fastest CAGR during the forecast period owing to increased import and installation of radiographic units in these countries
• Prominent companies operating in this market include Xoran Technologies, LLC, Ray, PLANMECA OY, VATECH, i-CAT, Dentsply Sirona, Owandy Radiology, Danaher (KaVo Kerr, Gendex, PaloDEx Group), Cefla S.C. (NewTom S.C), and J. MORITA CORP.

Lysosomal acid lipase deficiency (LAL-D) treatment market Size Worth USD 954 Million By 2025

The global lysosomal acid lipase deficiency (LAL-D) treatment market size is likely to reach USD 954 million by 2025, as per a new report by Grand View Research, Inc., exhibiting a 10.8% CAGR during the forecast period. High unmet needs, rising prevalence, and increasing uptake of enzyme replacement therapy are some of the primary factors driving the market.

LAL deficiency (LAL-D) is a rare type of lysosomal storage disorder in which patients are unable to breakdown cholesteryl esters and triglycerides due to a mutation in the LAL gene. As a result, there is an accumulation of lipids in the liver, spleen, and walls of blood vessels. LAL deficiency is a progressive disease with multi-systemic clinical manifestations, significant medical complications, and early mortality due to liver failure, especially among infants.

Until 2015, the global LAL deficiency treatment market witnessed modest growth due to lack of approved treatments for the disease. Medical care was limited to supportive care, with surgery and lipid-modifying drugs such as statins remained the mainstay for treatment. In 2015, approval of Alexion Pharma’s Kanuma (sebelipase alfa) marked entry of enzyme replacement therapy (ERT) in the LAL-D space. Kanuma is a hydrolytic lysosomal cholesterol ester and triacylglycerol specific enzyme, administered intravenously in patients with LAL deficiency. Currently, Kanuma is the only drug approved for both Wolman disease (WD) and Cholesteryl Ester Storage Disease (CESD) in the key markets.

Based on treatment, supportive care was the leading revenue contributor in the market in 2017. However, the ERT segment is expected to register the fastest growth during the forecast period, supported by continued uptake of Kanuma. Disease prognosis remains poor, as a majority of patients are either undiagnosed or misdiagnosed. Thus, there remains a strong need for extensive research to understand disease biology and develop effective therapeutic options with goal to overcome resistance and minimize toxicity.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/lysosomal-acid-lipase-deficiency-lal-d-treatment-market

Further key findings from the report suggest:

• CESD manifests later in life and is more prevalent among Caucasians and Hispanic populations, affecting approximately 1 in 300,000 individuals
• Germany is at the forefront of the Europe market and is driven by high disease prevalence and availability of drugs in the ERT class
• Approval of Kanuma in ERT class highlight a fundamental shift in treatment approach to LAL-D deficiency
• The ERT segment is estimated to be the fastest growing during the forecast period, owing to Kanuma’s first-mover advantage as the only long-term treatment in untapped LAL-D patient population pool
• Statins are anticipated to lose market share due to rising competition from generics within the class and increasing uptake of Alexion’s Kanuma
• Rising eligible patient population and limited therapeutic intervention for LAL deficiency offer strong commercial opportunity to players to invest in developing novel treatments in this market­
• Lack of awareness in disease diagnosis and delayed access to medications due to poor prognosis may restrain the growth of the market.

Disruptive Behavior Disorder Treatment Market Gain Worth USD 24.0 Billion By 2026

The global disruptive behavior disorder treatment market size is expected to reach USD 24.0 billion by 2026, according to a new report by Grand View Research, Inc. The market is projected to expand at a CAGR of 4.9% during the estimated period. Increasing cases of substance abuse across the globe are considered to be the key factors driving the market. Drug abuse is one of the major causes for acquiring oppositional defiant and conduct disorder as it enhances the symptoms for such conditions. Rising prevalence of mental disorders among children and teenagers is leading to increased awareness regarding the associated treatments, there by augmenting the market growth.

For instance, according to the Substance Abuse and Mental Health Services Administration (SAMHSA), globally, around 3.0% of children suffer from Oppositional Defiant Disorder (ODD) and around 8.0% of children suffer from Conduct Disorder (CD) per year. In recent times, majority of the parents of children aged between 5 and 14 years have undergone workshops and trainings for the treatment of above-mentioned conditions. Several hospitals, clinics, and institutes are organizing campaigns to create awareness about the relevant treatments among parents and physicians. For instance, the Child Mind Institute, Inc., organized a campaign named Speak Up for Kids, in May 2018, where children’s mental health issues and various treatments and policies related to these disorders were discussed. Therefore, such initiatives are expected to bolster the market growth over the forecast period.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/disruptive-behavior-disorders-market

Further key findings from the study suggest:

• In terms of revenue, oppositional defiant disorder segment is projected to ascend at a CAGR of 5.4% over the forecast period
• Increasing prevalence of such problems and awareness regarding their treatments will drive this segment
• Parenting therapy is expected to witness the fastest growth over the forecast period
• Frequent recommendation of parenting therapy by doctors, as it allows rapid recovery and is easy to follow, is expected to drive the segment
• Asia-Pacific market is expected to witness the fastest growth over the forecast period owing to the increasing cases of substance abuse
• Some of the key companies in the global disruptive behavior disorder treatment market are Highland Ridge Hospital, Lakeview Health, Boston Children's Hospital, INTEGRIS Health.

Minimally Invasive Surgical Instruments Market 2018 Upcoming Trends and Overview Forecast till 2025

The global minimally invasive surgical instruments market size is expected to reach USD 38.3 billion by 2025 according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 9.7% over the forecast period. The preference for Minimally Invasive Surgical (MIS) procedures is rising as they are less traumatic and they facilitate faster recover process than traditional open surgeries.

Minimal invasive technologies are designed to reduce trauma, blood loss, scarring, and chances of infection than traditional open surgeries. Patients can resume their daily activities in shorter time after these surgical procedures. In addition, the costs involved in minimally invasive surgeries are significantly less than in-patient and conventional open surgeries. Therefore, MIS procedures prove to be beneficial for patients as well as payers. The benefits of MIS in various areas of orthopedics have contributed to the growing demand for less traumatic alternatives with minimum tissue disruption of bones.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/minimally-invasive-surgical-instruments-market

Further key findings from the study suggest:

• Handheld instruments led the device segment in terms of revenue share in 2017. On the other hand, electrosurgical devices are expected to witness the fastest CAGR during the forecast period
• Orthopedic led the application segment in terms of revenue share in 2017 owing to easy surgical alternatives with minimum tissue disruption in the form of MIS procedures
• Continuous adoption of MIS techniques for spine related procedures has led to the expansion of procedural volumes for orthopedic MIS
• Hospital segment held a majority of the market share in 2017. On the other hand, the Ambulatory Surgical Centers segment is likely to experience the fastest growth in the forthcoming years
• Ambulatory surgical centers offer same day surgery and discharge at lower costs. At present, over 5,500 Medicare certified ambulatory care centers are present in U.S.
• North America held majority of the market share in 2017 due to the presence of supportive reimbursement framework for innovative MIS devices and procedures
• Medtronic; Abbott; NuVasive, Inc.; CONMED; Stryker; Smith & Nephew; Zimmer Biomet; and Intuitive Surgical, Inc. are some of the key players operating in the minimally invasive surgical instruments market.